⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966314 | 0.85 | — | — | |
| SCHEMBL5199675 | 0.83 | EPHX1 (0.58) | — | |
| SCHEMBL9555180 | 0.81 | EPHX1 (0.61) | — | |
| SCHEMBL9336292 | 0.81 | EPHX1 (0.61) | — | |
| SCHEMBL11661657 | 0.81 | MMP1 (0.46) | — | |
| SCHEMBL11661654 | 0.81 | MMP1 (0.46) | — | |
| SCHEMBL5265304 | 0.79 | — | — | |
| SCHEMBL43907 | 0.78 | — | — | |
| SCHEMBL15044537 | 0.77 | — | — | |
| SCHEMBL965543 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844822-B2 | Solid formulation and method for preventing or reducing coloration thereof | ELOBIX AB (SE) | 2023-12-19 | — | — | US | disclosed |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2023-10-19 | — | — | US | disclosed |
| US-11732006-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2023-08-22 | — | — | US | disclosed |
| US-20230109432-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2023-04-06 | — | — | US | disclosed |
| US-11261212-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2022-03-01 | — | — | US | disclosed |
| US-20210340175-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-10981952-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2021-04-20 | — | — | US | disclosed |
| EP-3777864-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200376071-A1 | SOLID FORMULATION AND METHOD FOR PREVENTING OR REDUCING COLORATION THEREOF | EA PHARMA CO., LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
| US-20200330545-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2020-10-22 | — | — | US | disclosed |
| US-6028033-A | FOR CONTROLLING UNDESIRED VEGETATION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-22 | — | — | US | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0815083-A1 | N-AMINOPYRIDONE DERIVATIVES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996037471-A1 | N-AMINOPYRIDONE DERIVATIVES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-28 | — | — | WO | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
| US-5302711-A | Ester cleavage process for use with β-lactams | ELI LILLY AND COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0557035-A2 | An ester cleavage process for use with beta-lactams | ELI LILLY AND COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0238357-B1 | 1,2,4-TRIAZINONE DERIVATIVES, THEIR PREPARATION AND USE | Sankyo Company Limited (JP) | 1991-05-29 | — | — | EP | disclosed |
| US-4898862-A | 1,2,4-triazinone derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0238357-A2 | 1,2,4-Triazinone derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-09-23 | — | — | EP | disclosed |